FDA Pulls Plug on Four COVID Tests: Time to Switch
Published Date: 5/29/2025
Notice
Summary
The FDA is ending emergency use permissions for four COVID-19 test kits from Pfizer, MAWD Laboratories, and Nuclein (now part of Molecular Diagnostics). This means these specific tests can no longer be used under emergency rules, as the companies asked for it. If you use these tests, check for updates soon—this change could affect testing options but won’t cost you extra.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Four COVID-19 Tests Lose Emergency Use
If you use one of these specific COVID-19 tests, they can no longer be used under the Emergency Use Authorization rules: Lucira COVID-19 All-In-One Test Kit; Lucira CHECK-IT COVID-19 Test Kit; MAWD Laboratories SARS-CoV-2 Dual Target by RT-PCR; and DASH SARS-CoV-2/S Test (Nuclein/Molecular Diagnostics). The companies asked the FDA to revoke the authorizations, so these tests may no longer be available under EUA and could change your local testing options, but the notice states this change will not cost you extra.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-09676, Freedom of Information Act (FOIA) Advisory Committee Meeting
The FOIA Advisory Committee is meeting soon to talk about how to make government information easier to get for everyone. This affects anyone who wants to access public records and could lead to faster, clearer responses from agencies. Stay tuned for updates that might change how and when you get your info, with no extra cost to you!
Next: 2025-09681, Growing, Harvesting, Processing, and Distribution of Poppy Seeds-Industry Practices Related to Opiate Alkaloids; Request for Information; Extension of Comment Period; Correction
The FDA fixed a mistake in their earlier notice about extending the time to share thoughts on how poppy seeds are grown, processed, and handled, especially concerning opiate chemicals. This update mainly affects farmers, processors, and distributors of poppy seeds who want to weigh in. The comment period is still open, so don’t miss your chance to speak up!